Connect with us

Fibromyalgia

What is fibromyalgia – and can cannabis help?

Published

on

One treatment which is growing significantly in terms of both research and usage is cannabis.

With around one in 20 people in the UK and an estimated three to six per cent of the world’s population diagnosed, fibromyalgia is one of the most common pain conditions in the world. 

Anyone can develop fibromyalgia – it affects around seven times as many women as men but can develop in either gender at any age – though its wide-ranging symptoms can make it a difficult condition to diagnose.

Alongside chronic pain, those affected may suffer with extreme tiredness, muscle stiffness, headaches, irritable bowel syndrome and problems with mental processes such as memory and concentration – all of which can be attributed to a number of other ailments. 

While the exact cause of the condition is unknown, it’s thought to be related to abnormal levels of certain chemicals in the brain and changes in the way the central nervous system processes pain messages carried around the body. In many cases, it can be triggered by a physically or emotionally stressful event such as injury, giving birth or the death of a loved one. 

Unfortunately, there is no known cure for fibromyalgia and no remedy to get rid of pain entirely. Instead, patients search for methods to alleviate symptoms, with many opting for a combination of treatments.

One which is growing significantly in terms of both research and usage is cannabis.

The remedy has long been associated with pain relief and as evidence of its benefits mounts, many fibromyalgia patients are choosing to give products such as gels and capsules a try. 

In 2019, a study of 367 patients found that pain intensity decreased when treated with CBD. This was supported by Chaves, Bittencourt and Pelegrini in 2020, with the team finding that phytocannabinoids can serve as an ‘affordable yet well-tolerated therapy’ for symptom relief and quality of life improvements.  

As usage rises, professionals are coming round to the idea of CBD as a prescribed treatment in fibromyalgia, and in 2018 Carly Barton of Brighton became the UK’s first fibromyalgia patient to receive a prescription for medical cannabis. Prior to that, she, along with thousands of others, had been paying up to £2,500 for three months’ treatment. 

Despite many sufferers being reluctant to exercise for fear of aggravating symptoms, it’s another effective way to alleviate pain. Aerobic, resistance and stretching exercises have all been known to relieve pain and stiffness, increase strength and improve mobility in patients, while relaxation exercises such as yoga and t’ai chi can help with difficulty sleeping. 

Research has repeatedly backed up these claims and shown that regular aerobic exercise can improve pain, function and overall quality of life, with a 2017 study stating that “aerobic and muscle strengthening exercises are the most effective way of reducing pain and improving global wellbeing in people with fibromyalgia and that stretching and aerobic exercises increase health-related quality of life”.

While regular painkillers may provide some benefits to fibromyalgia symptoms, one of the most commonly prescribed medications for the condition is antidepressants. The medication is known to boost the levels of certain chemicals (neurotransmitters) that carry messages to and from the brain, and with low levels of neurotransmitters thought to be a factor in fibromyalgia, it’s believed that this boost may ease the widespread pain associated with the condition. 

Many professionals also believe that talking therapies, such as cognitive behavioural therapy (CBT) and counselling, are an effective way to manage symptoms and improve low mood associated with fibromyalgia.  

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.